JP2005512987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512987A5 JP2005512987A5 JP2003541333A JP2003541333A JP2005512987A5 JP 2005512987 A5 JP2005512987 A5 JP 2005512987A5 JP 2003541333 A JP2003541333 A JP 2003541333A JP 2003541333 A JP2003541333 A JP 2003541333A JP 2005512987 A5 JP2005512987 A5 JP 2005512987A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- composition
- rankl
- antigenic determinant
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 36
- 239000000427 antigen Substances 0.000 claims 34
- 230000000890 antigenic Effects 0.000 claims 32
- 102000014128 RANK Ligand Human genes 0.000 claims 31
- 108010025832 RANK Ligand Proteins 0.000 claims 31
- 102000038129 antigens Human genes 0.000 claims 31
- 108091007172 antigens Proteins 0.000 claims 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 102000007312 Recombinant Proteins Human genes 0.000 claims 23
- 108010033725 Recombinant Proteins Proteins 0.000 claims 23
- 239000002245 particle Substances 0.000 claims 17
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 6
- 229960005486 vaccines Drugs 0.000 claims 6
- 241000700721 Hepatitis B virus Species 0.000 claims 3
- 101000047749 TNFSF11 Proteins 0.000 claims 3
- 102000019620 human TNFSF11 protein Human genes 0.000 claims 3
- 230000003053 immunization Effects 0.000 claims 3
- 208000003432 Bone Disease Diseases 0.000 claims 2
- 241000709738 Enterobacteria phage fr Species 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241001672158 Acinetobacter phage AP205 Species 0.000 claims 1
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000709737 Enterobacteria phage GA Species 0.000 claims 1
- 241001261579 Enterobacteria phage M11 Species 0.000 claims 1
- 241001278075 Enterobacteria phage MX1 Species 0.000 claims 1
- 241001278054 Enterobacteria phage NL95 Species 0.000 claims 1
- 241000709747 Enterobacteria phage R17 Species 0.000 claims 1
- 241000709743 Enterobacteria phage SP Species 0.000 claims 1
- 241000709739 Enterobacteria phage f2 Species 0.000 claims 1
- 241000709744 Enterobacterio phage MS2 Species 0.000 claims 1
- 241001534160 Escherichia virus Qbeta Species 0.000 claims 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000714209 Norwalk virus Species 0.000 claims 1
- 101710043203 P23p89 Proteins 0.000 claims 1
- 241001505332 Polyomavirus sp. Species 0.000 claims 1
- 241000709749 Pseudomonas phage PP7 Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000710960 Sindbis virus Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001177 retroviral Effects 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
Claims (31)
(b)少なくとも1つの抗原または抗原決定基と
を含み、前記抗原または前記抗原決定基が、RANKLタンパク質、RANKL断片またはRANKLペプチドであり、
前記少なくとも1つの抗原または抗原決定基が前記ウイルス様粒子に結合している組成物。 (A) virus-like particles;
(B) at least one antigen or antigenic determinant, wherein the antigen or antigenic determinant is a RANKL protein, RANKL fragment or RANKL peptide;
A composition wherein the at least one antigen or antigenic determinant is bound to the virus-like particle.
(a)B型肝炎ウイルスの組換えタンパク質、 (A) hepatitis B virus recombinant protein,
(b)麻疹ウイルスの組換えタンパク質、 (B) measles virus recombinant protein,
(c)シンドビスウイルスの組換えタンパク質、 (C) a Sindbis virus recombinant protein,
(d)ロタウイルスの組換えタンパク質、 (D) a recombinant protein of rotavirus,
(e)口蹄疫ウイルスの組換えタンパク質、 (E) a foot-and-mouth disease virus recombinant protein,
(f)レトロウイルスの組換えタンパク質、 (F) a retroviral recombinant protein,
(g)ノーウォークウイルスの組換えタンパク質、 (G) Norwalk virus recombinant protein,
(h)アルファウイルスの組換えタンパク質、 (H) alphavirus recombinant protein,
(i)ヒトパピローマウイルスの組換えタンパク質、 (I) a recombinant protein of human papillomavirus,
(j)ポリオーマウイルスの組換えタンパク質、 (J) a polyomavirus recombinant protein,
(k)バクテリオファージの組換えタンパク質、 (K) a recombinant protein of bacteriophage,
(l)RNAファージの組換えタンパク質、 (L) a recombinant protein of RNA phage,
(m)Tyの組換えタンパク質、 (M) a Ty recombinant protein,
(n)(a)〜(m)の組換えタンパク質のいずれかの断片 (N) A fragment of any of the recombinant proteins (a) to (m)
からなる群から選択された組換えタンパク質またはその断片を含む、請求項1に記載の組成物。 The composition of claim 1 comprising a recombinant protein or fragment thereof selected from the group consisting of:
(a)B型肝炎ウイルスの組換えタンパク質;及び
(b)RNAファージの組換えタンパク質、
からなる群から選択された組換えタンパク質またはその断片を含む、請求項1に記載の組成物。 The virus-like particles are
(A) a recombinant protein of hepatitis B virus; and (b) a recombinant protein of RNA phage,
The composition of claim 1 comprising a recombinant protein or fragment thereof selected from the group consisting of:
(a)バクテリオファージQβ、 (A) bacteriophage Qβ,
(b)バクテリオファージR17、 (B) bacteriophage R17,
(c)バクテリオファージfr、 (C) bacteriophage fr,
(d)バクテリオファージGA、 (D) bacteriophage GA,
(e)バクテリオファージSP、 (E) bacteriophage SP,
(f)バクテリオファージMS2、 (F) bacteriophage MS2,
(g)バクテリオファージM11、 (G) bacteriophage M11,
(h)バクテリオファージMX1、 (H) bacteriophage MX1,
(i)バクテリオファージNL95、 (I) bacteriophage NL95,
(k)バクテリオファージf2、 (K) bacteriophage f2,
(l)バクテリオファージPP7、および (L) bacteriophage PP7, and
(m)バクテリオファージAP205 (M) Bacteriophage AP205
からなる群から選択される、請求項1に記載の組成物。 The composition of claim 1, wherein the composition is selected from the group consisting of:
(a)配列番号79のアミノ酸配列、 (A) the amino acid sequence of SEQ ID NO: 79,
(b)配列番号80のアミノ酸配列、 (B) the amino acid sequence of SEQ ID NO: 80,
(c)配列番号81のアミノ酸配列、 (C) the amino acid sequence of SEQ ID NO: 81,
(d)配列番号82のアミノ酸配列、 (D) the amino acid sequence of SEQ ID NO: 82,
(e)配列番号83のアミノ酸配列、 (E) the amino acid sequence of SEQ ID NO: 83,
(f)配列番号84のアミノ酸配列、 (F) the amino acid sequence of SEQ ID NO: 84,
(g)配列番号100のアミノ酸配列、 (G) the amino acid sequence of SEQ ID NO: 100,
(h)配列番号101のアミノ酸配列、および (H) the amino acid sequence of SEQ ID NO: 101, and
(i)配列番号79〜84、100、101のいずれかの断片のアミノ酸配列 (I) The amino acid sequence of any fragment of SEQ ID NOs: 79-84, 100, 101
からなる群から選択されたアミノ酸配列を有する、請求項1に記載の組成物。 The composition of claim 1 having an amino acid sequence selected from the group consisting of:
(a)配列番号87のアミノ酸配列、 (A) the amino acid sequence of SEQ ID NO: 87,
(b)配列番号88のアミノ酸配列、 (B) the amino acid sequence of SEQ ID NO: 88,
(c)配列番号89のアミノ酸配列、 (C) the amino acid sequence of SEQ ID NO: 89,
(d)配列番号90のアミノ酸配列、 (D) the amino acid sequence of SEQ ID NO: 90,
(e)配列番号91のアミノ酸配列、 (E) the amino acid sequence of SEQ ID NO: 91,
(f)配列番号92のアミノ酸配列、 (F) the amino acid sequence of SEQ ID NO: 92,
(f)配列番号93のアミノ酸配列、および (F) the amino acid sequence of SEQ ID NO: 93, and
(k)配列番号87〜93のいずれかの断片のアミノ酸配列 (K) Amino acid sequence of any fragment of SEQ ID NOs: 87 to 93
からなる群から選択されたアミノ酸配列を含むRANKLペプチドである、請求項1に記載の組成物。 The composition of claim 1, which is a RANKL peptide comprising an amino acid sequence selected from the group consisting of.
(i)前記抗原または抗原決定基との天然でない結着部位、 (I) a non-natural binding site with the antigen or antigenic determinant;
(ii)前記抗原または抗原決定基との天然の結着部位 (Ii) a natural binding site with the antigen or antigenic determinant
からなる群から選択された少なくとも1つの第2の結着部位をさらに含む、請求項1に記載の組成物。 The composition of claim 1, further comprising at least one second binding site selected from the group consisting of:
(a)配列番号104のアミノ酸配列、 (A) the amino acid sequence of SEQ ID NO: 104,
(b)配列番号105のアミノ酸配列、 (B) the amino acid sequence of SEQ ID NO: 105,
(c)配列番号106のアミノ酸配列、 (C) the amino acid sequence of SEQ ID NO: 106,
(d)配列番号107のアミノ酸配列、 (D) the amino acid sequence of SEQ ID NO: 107,
(e)配列番号108のアミノ酸配列、 (E) the amino acid sequence of SEQ ID NO: 108,
(f)配列番号109のアミノ酸配列、 (F) the amino acid sequence of SEQ ID NO: 109,
(g)配列番号110のアミノ酸配列、および (G) the amino acid sequence of SEQ ID NO: 110, and
(h)配列番号104〜110のいずれかの断片のアミノ酸配列 (H) the amino acid sequence of any fragment of SEQ ID NOs: 104-110
からなる群から選択されたアミノ酸配列を含む、請求項14に記載の組成物。 15. The composition of claim 14, comprising an amino acid sequence selected from the group consisting of:
(b)製薬的に許容可能な担体、
を含んでなる製薬的組成物。 (A ) the composition of claim 1, and
(B) a pharmaceutically acceptable carrier,
A pharmaceutical composition comprising:
(b)少なくとも1つの抗原又は抗原決定基
を含み、前記抗原又は前記抗原決定基がRANKLタンパク質、RANKL断片又はRANKLペプチド、及び、前記の少なくとも1つの抗原又は抗原決定基が前記ウイルス様粒子と結合し、及び、好ましくは前記得ワクチン組成物がさらにアジュバンドを含む組成物を含んでなるワクチン組成物。 (A ) virus-like particles, and
(B) at least one antigen or antigenic determinant
Wherein the antigen or the antigenic determinant binds to the RANKL protein, RANKL fragment or RANKL peptide, and the at least one antigen or antigenic determinant binds to the virus-like particle, and preferably the obtained vaccine composition A vaccine composition comprising a composition further comprising adjuvant.
(b)抗原又は抗原決定基がRANKLタンパク質、RANKL断片又はRANKLペプチドである、少なくとも1つの前記抗原又は抗原決定基を提供すること、 (B) providing at least one said antigen or antigenic determinant wherein the antigen or antigenic determinant is a RANKL protein, RANKL fragment or RANKL peptide;
(c)前記の少なくとも1つの抗原又は抗原決定基が前記ウイルス様粒子と結合するように、前記ウイルス様粒子と前記の少なくとも1つの抗原又は抗原決定基を組み合わせることを含んでなる、請求項1に記載の組成物を製造する工程。 (C) combining the virus-like particle and the at least one antigen or antigenic determinant such that the at least one antigen or antigenic determinant binds to the virus-like particle. A process for producing the composition described in 1.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33104501P | 2001-11-07 | 2001-11-07 | |
US60/331,045 | 2001-11-07 | ||
US10/050,902 | 2002-01-18 | ||
US10/050,902 US7264810B2 (en) | 2001-01-19 | 2002-01-18 | Molecular antigen array |
US39663502P | 2002-07-19 | 2002-07-19 | |
US60/396,635 | 2002-07-19 | ||
PCT/EP2002/012449 WO2003039225A2 (en) | 2001-11-07 | 2002-11-07 | Antigen arrays comprising rankl for treatment of bone disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009255878A Division JP2010090127A (en) | 2001-11-07 | 2009-11-09 | Antigen array for treating bone disease |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005512987A JP2005512987A (en) | 2005-05-12 |
JP2005512987A5 true JP2005512987A5 (en) | 2005-12-22 |
JP4658475B2 JP4658475B2 (en) | 2011-03-23 |
Family
ID=31721335
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003541333A Expired - Fee Related JP4658475B2 (en) | 2001-11-07 | 2002-11-07 | Antigen array for bone disease treatment |
JP2009255878A Pending JP2010090127A (en) | 2001-11-07 | 2009-11-09 | Antigen array for treating bone disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009255878A Pending JP2010090127A (en) | 2001-11-07 | 2009-11-09 | Antigen array for treating bone disease |
Country Status (3)
Country | Link |
---|---|
JP (2) | JP4658475B2 (en) |
MX (1) | MXPA04003900A (en) |
RU (1) | RU2322258C2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101267834B (en) * | 2005-09-28 | 2013-06-05 | 赛托斯生物技术公司 | Interleukin-1 conjugates and uses thereof |
JP6034285B2 (en) * | 2010-05-28 | 2016-11-30 | ゾエティス・ベルジャム・エス・アー | Antigen and immunoregulatory vaccines and cholesterol and uses thereof |
JP6409528B2 (en) * | 2014-11-27 | 2018-10-24 | Jnc株式会社 | Porous cellulose particles having an ion exchange group containing amino groups and a hydrophobic group containing butyl groups, a chromatography carrier containing the same, and a method for purifying virus-like particles of hepatitis B virus |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9114003D0 (en) * | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
GB9213601D0 (en) * | 1992-06-26 | 1992-08-12 | Mastico Robert A | Protein based delivery system |
ES2258869T3 (en) * | 1998-10-21 | 2006-09-01 | The United States Government As Represented By The Department Of Health And Human Services | VIRUS SIMILAR PARTICLES FOR THE INDUCTION OF AUTO ANTIBODIES. |
-
2002
- 2002-11-07 MX MXPA04003900A patent/MXPA04003900A/en active IP Right Grant
- 2002-11-07 JP JP2003541333A patent/JP4658475B2/en not_active Expired - Fee Related
- 2002-11-07 RU RU2004117075/15A patent/RU2322258C2/en not_active IP Right Cessation
-
2009
- 2009-11-09 JP JP2009255878A patent/JP2010090127A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005104565A (en) | GRAELIN CARRIER CONJUGATES | |
JP5302671B2 (en) | Cat allergen conjugates and uses thereof | |
JP5084103B2 (en) | Hapten carrier conjugates and uses thereof | |
RU2005104824A (en) | VACCINE COMPOSITIONS CONTAINING ANTIGEN KITS AS AMYLOID BETA 1-6 | |
ES2317711T3 (en) | MOLECULAR PRESENTATION OF ALLERGENS, METHODS OF PREPARATION AND USE. | |
RU2322257C2 (en) | COMPOSITIONS COMPRISING CpG-OLIGONUCLEOTIDES AND VIRUS-LIKE PARTICLES FOR USING AS ADJUVANTS | |
JP2005507388A5 (en) | ||
JP2005517632A5 (en) | ||
JP2006523189A5 (en) | ||
JP2008535800A5 (en) | ||
JP2008523132A (en) | IL-15 antigen array and method of use thereof | |
JP2008517975A (en) | Gastric acid secretion inhibitory polypeptide (GIP) antigen assay and uses thereof | |
MX2007003171A (en) | Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide. | |
JP2008501658A (en) | Medical use of non-human TNF-peptide carrier conjugates | |
RU2010129538A (en) | NGF CONJUGATES AND THEIR APPLICATION | |
JP2006504653A5 (en) | ||
WO2008074895A1 (en) | Circular ccr5 peptide conjugates and uses thereof | |
JP2005514333A5 (en) | ||
RU2006130006A (en) | GRAELIN CARRIER CONJUGATES | |
JP2006504644A5 (en) | ||
JP2008543810A (en) | Antigen conjugates and uses thereof | |
RU2004117072A (en) | ANTIGENIC MATRIXES FOR TREATMENT OF ALLERGIC EOSINOPHILIC DISEASES | |
JP2005512987A5 (en) | ||
RU2004117075A (en) | ANTIGENIC MATRIX FOR THE TREATMENT OF BONE DISEASE | |
WO2007039458A2 (en) | Hiv peptide conjugates and uses thereof |